secwatch.observer — SEC 8-K summary
======================================

Issuer:     OCULAR THERAPEUTIX, INC (OCUL)
CIK:        0001393434
Form:       8-K
Filed at:   2023-10-04T23:59:59+00:00
Accession:  0001104659-23-106651
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocular Therapeutix CEO presents OTX-TKI program at EURETINA conference
----------------------------------------------------------------------

- CEO Antony Mattessich presented on OTX-TKI for wet AMD at EURETINA Innovation Spotlight on Oct 4, 2023.
- Presentation provided an overview of the investigational tyrosine kinase inhibitor therapy for retinal vascular diseases.
- No new clinical data, financial guidance, or material updates were disclosed in the slides.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1393434/000110465923106651/0001104659-23-106651-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1393434/000110465923106651/tm2327605d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-106651

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer